Cholangiocarcinomas express Fas ligand and disable the Fas receptor

Florencia Que, Vy A. Phan, Van H. Phan, Adrianne Celli, Kenneth Batts, Nicholas F La Russo, Gregory James Gores

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Cholangiocarcinoma is a highly-malignant adenocarcinoma originating from cholangiocytes. Current concepts support escape from immune surveillance using aberrant expression of Fas ligand (FasL) and dysregulation of receptor (FasR) signaling as a potential mechanism for tumor progression. Our aims were to determine if altered expression of FasR and FasL or changes in expression of FLICE inhibitor (I-FLICE) allow cholangiocarcinoma cells to escape immune surveillance. Human cholangiocarcinoma cell lines were evaluated for the functional expression of FasR and FasL by (1) quantitating apoptosis after incubation of cells with agonistic antibodies and (2) an in vitro cell death assay involving coculture of cholangiocarcinoma cells with Fas-sensitive thymocytes. I-FLICE antisense treatment was performed by stable transfection with complementary DNA (cDNA) for I-FLICE in the reverse orientation. We found that normal cholangiocytes in vivo express FasL. Human cholangiocarcinoma cell lines express both FasL and FasR and I-FLICE. FasL expressed by cholangiocarcinomas in vitro induced lymphocyte cell death (70% after 24 hours). Despite the expression of FasR, exposure of the cells to agonistic antibodies (500 ng/mL) induced only minimal apoptosis in the Jurkat cells. Antisense treatment of cholangiocarcinomas in vitro with I-FLICE reduced protein expression of I-FLICE by 90% to 95% and increased Fas- mediated apoptosis 2-fold. We concluded that cholangiocarcinomas escape immune surveillance either by disabling FasR signaling through the expression of I-FLICE and/or increased FasL expression to induce apoptosis of invading T cells. Reduction of I-FLICE expression in cholangiocarcinoma cells restored Fas-mediated apoptosis. Therapeutic maneuvers to inhibit expression of I- FLICE may aid in the treatment of cholangiocarcinoma.

Original languageEnglish (US)
Pages (from-to)1398-1404
Number of pages7
JournalHepatology
Volume30
Issue number6
StatePublished - 1999

Fingerprint

CD95 Antigens
Fas Ligand Protein
Cholangiocarcinoma
Apoptosis
Cell Death
Cell Line
Jurkat Cells
Caspase 8
Antibodies
Thymocytes
Coculture Techniques
Transfection
Adenocarcinoma
Complementary DNA
Lymphocytes

ASJC Scopus subject areas

  • Hepatology

Cite this

Que, F., Phan, V. A., Phan, V. H., Celli, A., Batts, K., La Russo, N. F., & Gores, G. J. (1999). Cholangiocarcinomas express Fas ligand and disable the Fas receptor. Hepatology, 30(6), 1398-1404.

Cholangiocarcinomas express Fas ligand and disable the Fas receptor. / Que, Florencia; Phan, Vy A.; Phan, Van H.; Celli, Adrianne; Batts, Kenneth; La Russo, Nicholas F; Gores, Gregory James.

In: Hepatology, Vol. 30, No. 6, 1999, p. 1398-1404.

Research output: Contribution to journalArticle

Que, F, Phan, VA, Phan, VH, Celli, A, Batts, K, La Russo, NF & Gores, GJ 1999, 'Cholangiocarcinomas express Fas ligand and disable the Fas receptor', Hepatology, vol. 30, no. 6, pp. 1398-1404.
Que F, Phan VA, Phan VH, Celli A, Batts K, La Russo NF et al. Cholangiocarcinomas express Fas ligand and disable the Fas receptor. Hepatology. 1999;30(6):1398-1404.
Que, Florencia ; Phan, Vy A. ; Phan, Van H. ; Celli, Adrianne ; Batts, Kenneth ; La Russo, Nicholas F ; Gores, Gregory James. / Cholangiocarcinomas express Fas ligand and disable the Fas receptor. In: Hepatology. 1999 ; Vol. 30, No. 6. pp. 1398-1404.
@article{ff35170e41f648ff95fde5005bced829,
title = "Cholangiocarcinomas express Fas ligand and disable the Fas receptor",
abstract = "Cholangiocarcinoma is a highly-malignant adenocarcinoma originating from cholangiocytes. Current concepts support escape from immune surveillance using aberrant expression of Fas ligand (FasL) and dysregulation of receptor (FasR) signaling as a potential mechanism for tumor progression. Our aims were to determine if altered expression of FasR and FasL or changes in expression of FLICE inhibitor (I-FLICE) allow cholangiocarcinoma cells to escape immune surveillance. Human cholangiocarcinoma cell lines were evaluated for the functional expression of FasR and FasL by (1) quantitating apoptosis after incubation of cells with agonistic antibodies and (2) an in vitro cell death assay involving coculture of cholangiocarcinoma cells with Fas-sensitive thymocytes. I-FLICE antisense treatment was performed by stable transfection with complementary DNA (cDNA) for I-FLICE in the reverse orientation. We found that normal cholangiocytes in vivo express FasL. Human cholangiocarcinoma cell lines express both FasL and FasR and I-FLICE. FasL expressed by cholangiocarcinomas in vitro induced lymphocyte cell death (70{\%} after 24 hours). Despite the expression of FasR, exposure of the cells to agonistic antibodies (500 ng/mL) induced only minimal apoptosis in the Jurkat cells. Antisense treatment of cholangiocarcinomas in vitro with I-FLICE reduced protein expression of I-FLICE by 90{\%} to 95{\%} and increased Fas- mediated apoptosis 2-fold. We concluded that cholangiocarcinomas escape immune surveillance either by disabling FasR signaling through the expression of I-FLICE and/or increased FasL expression to induce apoptosis of invading T cells. Reduction of I-FLICE expression in cholangiocarcinoma cells restored Fas-mediated apoptosis. Therapeutic maneuvers to inhibit expression of I- FLICE may aid in the treatment of cholangiocarcinoma.",
author = "Florencia Que and Phan, {Vy A.} and Phan, {Van H.} and Adrianne Celli and Kenneth Batts and {La Russo}, {Nicholas F} and Gores, {Gregory James}",
year = "1999",
language = "English (US)",
volume = "30",
pages = "1398--1404",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Cholangiocarcinomas express Fas ligand and disable the Fas receptor

AU - Que, Florencia

AU - Phan, Vy A.

AU - Phan, Van H.

AU - Celli, Adrianne

AU - Batts, Kenneth

AU - La Russo, Nicholas F

AU - Gores, Gregory James

PY - 1999

Y1 - 1999

N2 - Cholangiocarcinoma is a highly-malignant adenocarcinoma originating from cholangiocytes. Current concepts support escape from immune surveillance using aberrant expression of Fas ligand (FasL) and dysregulation of receptor (FasR) signaling as a potential mechanism for tumor progression. Our aims were to determine if altered expression of FasR and FasL or changes in expression of FLICE inhibitor (I-FLICE) allow cholangiocarcinoma cells to escape immune surveillance. Human cholangiocarcinoma cell lines were evaluated for the functional expression of FasR and FasL by (1) quantitating apoptosis after incubation of cells with agonistic antibodies and (2) an in vitro cell death assay involving coculture of cholangiocarcinoma cells with Fas-sensitive thymocytes. I-FLICE antisense treatment was performed by stable transfection with complementary DNA (cDNA) for I-FLICE in the reverse orientation. We found that normal cholangiocytes in vivo express FasL. Human cholangiocarcinoma cell lines express both FasL and FasR and I-FLICE. FasL expressed by cholangiocarcinomas in vitro induced lymphocyte cell death (70% after 24 hours). Despite the expression of FasR, exposure of the cells to agonistic antibodies (500 ng/mL) induced only minimal apoptosis in the Jurkat cells. Antisense treatment of cholangiocarcinomas in vitro with I-FLICE reduced protein expression of I-FLICE by 90% to 95% and increased Fas- mediated apoptosis 2-fold. We concluded that cholangiocarcinomas escape immune surveillance either by disabling FasR signaling through the expression of I-FLICE and/or increased FasL expression to induce apoptosis of invading T cells. Reduction of I-FLICE expression in cholangiocarcinoma cells restored Fas-mediated apoptosis. Therapeutic maneuvers to inhibit expression of I- FLICE may aid in the treatment of cholangiocarcinoma.

AB - Cholangiocarcinoma is a highly-malignant adenocarcinoma originating from cholangiocytes. Current concepts support escape from immune surveillance using aberrant expression of Fas ligand (FasL) and dysregulation of receptor (FasR) signaling as a potential mechanism for tumor progression. Our aims were to determine if altered expression of FasR and FasL or changes in expression of FLICE inhibitor (I-FLICE) allow cholangiocarcinoma cells to escape immune surveillance. Human cholangiocarcinoma cell lines were evaluated for the functional expression of FasR and FasL by (1) quantitating apoptosis after incubation of cells with agonistic antibodies and (2) an in vitro cell death assay involving coculture of cholangiocarcinoma cells with Fas-sensitive thymocytes. I-FLICE antisense treatment was performed by stable transfection with complementary DNA (cDNA) for I-FLICE in the reverse orientation. We found that normal cholangiocytes in vivo express FasL. Human cholangiocarcinoma cell lines express both FasL and FasR and I-FLICE. FasL expressed by cholangiocarcinomas in vitro induced lymphocyte cell death (70% after 24 hours). Despite the expression of FasR, exposure of the cells to agonistic antibodies (500 ng/mL) induced only minimal apoptosis in the Jurkat cells. Antisense treatment of cholangiocarcinomas in vitro with I-FLICE reduced protein expression of I-FLICE by 90% to 95% and increased Fas- mediated apoptosis 2-fold. We concluded that cholangiocarcinomas escape immune surveillance either by disabling FasR signaling through the expression of I-FLICE and/or increased FasL expression to induce apoptosis of invading T cells. Reduction of I-FLICE expression in cholangiocarcinoma cells restored Fas-mediated apoptosis. Therapeutic maneuvers to inhibit expression of I- FLICE may aid in the treatment of cholangiocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0032697242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032697242&partnerID=8YFLogxK

M3 - Article

C2 - 10573518

AN - SCOPUS:0032697242

VL - 30

SP - 1398

EP - 1404

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -